-
Add to Cart The item has been addedB646355-25mgBRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC 50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can -
Add to Cart The item has been addedB646355-50mgBRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC 50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can -
Add to Cart The item has been addedB646355-5mgBRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC 50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can -
Add to Cart The item has been addedB654553-1mlBRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC 50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can -
Add to Cart The item has been addedB646758-100mgBRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC 50 s of 4.5 and 1.8 nM, respectively)Form:SolidIC50&: Target:BRD7, BRD9. -
Add to Cart The item has been addedB646758-10mgBRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC 50 s of 4.5 and 1.8 nM, respectively)Form:SolidIC50&: Target:BRD7, BRD9. -
Add to Cart The item has been addedB646758-50mgBRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC 50 s of 4.5 and 1.8 nM, respectively)Form:SolidIC50&: Target:BRD7, BRD9. -
Add to Cart The item has been addedB646758-5mgBRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC 50 s of 4.5 and 1.8 nM, respectively)Form:SolidIC50&: Target:BRD7, BRD9. -
Add to Cart The item has been addedB650447-100mgBRD7586 is a cell-permeable small-molecule inhibitor of SpCas9. BRD7586 is the smallest known anti-CRISPR.In VitroBRD7586 specifically engages SpCas9 but not Cas12a in cells. BRD7586 (0-20 μM: 24 h) dose-dependently inhibits SpCas9 in the -
Add to Cart The item has been addedB650447-10mgBRD7586 is a cell-permeable small-molecule inhibitor of SpCas9. BRD7586 is the smallest known anti-CRISPR.In VitroBRD7586 specifically engages SpCas9 but not Cas12a in cells. BRD7586 (0-20 μM: 24 h) dose-dependently inhibits SpCas9 in the -
Add to Cart The item has been addedB650447-25mgBRD7586 is a cell-permeable small-molecule inhibitor of SpCas9. BRD7586 is the smallest known anti-CRISPR.In VitroBRD7586 specifically engages SpCas9 but not Cas12a in cells. BRD7586 (0-20 μM: 24 h) dose-dependently inhibits SpCas9 in the -
Add to Cart The item has been addedB650447-50mgBRD7586 is a cell-permeable small-molecule inhibitor of SpCas9. BRD7586 is the smallest known anti-CRISPR.In VitroBRD7586 specifically engages SpCas9 but not Cas12a in cells. BRD7586 (0-20 μM: 24 h) dose-dependently inhibits SpCas9 in the
